Home Immunology & Inflammation E3 ligase Ligand chemical - Immunology & Inflammation related modulator - E3 Ligase inhibitor - Apoptosis related activator Iberdomide (CC220) For research use only.

Iberdomide (CC220)

Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.

Iberdomide (CC220) Chemical Structure

Iberdomide (CC220) Chemical Structure

CAS No. 1323403-33-3

Purity & Quality Control

Iberdomide (CC220) Related Products

Biological Activity

Description Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
Targets
cereblon [1]
60 nM
In vitro
In vitro

In cellular degradation assays, treatment with CC-220 results in the loss of Ikaros protein levels with an EC50 of 1 nM. CC-220 is similarly potent toward Aiolos, with an EC50 of 0.5 nM[1].

CC-220 is a potent anti-proliferative and pro-apoptotic compound that shows activity in several MM cell line categories. CC-220 induces PBMC-mediated killing of all MM cell lines regardless of the level of Cereblon expression and cell autonomous sensitivity. CC-220 acts through binding of Cereblon, leading to the degradation of the hematopoietic transcription factors Ikaros and Aiolos, followed by disruption of the MM promoting c-Myc/IRF4 axis[2].
Cell Research Cell lines DF15 cells
Concentrations 60 nM
Incubation Time 5 h
Method

Cells were treated with CC-220 for 5 h before harvest.
Experimental Result Images Methods Biomarkers Images PMID
Western blot Aiolos / Ikaros IKZF1 / IKZF3 / ZFP91 / CK1α / CBRN / UBE2G1 28848067
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06216158 Recruiting
Multiple Myeloma
University of Heidelberg Medical Center|KKS Netzwerk|Wuerzburg University Hospital|Sanofi|Bristol-Myers Squibb
 April 5 2024 Phase 3
NCT06215118 Recruiting
Multiple Myeloma
Pfizer|Bristol-Myers Squibb
 February 20 2024 Phase 1
NCT05827016 Recruiting
Multiple Myeloma
Bristol-Myers Squibb
 June 22 2023 Phase 3
NCT05560399 Enrolling by invitation
Multiple Myeloma
Icahn School of Medicine at Mount Sinai|Multiple Myeloma Research Consortium|Bristol-Myers Squibb
 February 6 2023 Early Phase 1

Chemical Information & Solubility

Molecular Weight 449.50 Formula

C25H27N3O5
CAS No. 1323403-33-3 SDF --
Smiles C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 90 mg/mL ( (200.22 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Iberdomide (CC220) | Iberdomide (CC220) supplier | purchase Iberdomide (CC220) | Iberdomide (CC220) cost | Iberdomide (CC220) manufacturer | order Iberdomide (CC220) | Iberdomide (CC220) distributor